Low-Risk Therapy

Phase 2Small molecule

SSt. Jude Children's Research Hospital

Low-Risk Therapy is one of 13 small molecule programs targeting Ependymoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EpendymomaActive, not recruiting

EpendymomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Ependymoma

#DrugCompanyPhaseTrials

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Bicnu

Adrucil

Oncovin

1 5

Vepesid

AAvyxa

Phase 3

6 6

Cytoxan

BBaxter Healthcare Corporation

Phase 3

4 7

Paraplatin

AAvyxa

Phase 3

4 8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 9

Neupogen

EEastern Cooperative Oncology Group

Phase 3

2 10

Mesnex

BBaxter Healthcare Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ependymoma1 trial

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT00602667·293 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Low-Risk Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low-Risk Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low-Risk Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Jude Children's Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSt. Jude Children's Research Hospital

Low-Risk Therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ependymoma1 trial

References

Drug Info

Quick Facts

Related News